Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;53(10):6698-6708.
doi: 10.1007/s12035-015-9601-8. Epub 2015 Dec 10.

Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy

Affiliations
Review

Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy

Ling Liu et al. Mol Neurobiol. 2016 Dec.

Abstract

Huntington's disease (HD) is an incurable neurodegenerative disorder that is characterized by motor dysfunction, cognitive impairment, and behavioral abnormalities. It is an autosomal dominant disorder caused by a CAG repeat expansion in the huntingtin gene, resulting in progressive neuronal loss predominately in the striatum and cortex. Despite the discovery of the causative gene in 1993, the exact mechanisms underlying HD pathogenesis have yet to be elucidated. Treatments that slow or halt the disease process are currently unavailable. Recent advances in induced pluripotent stem cell (iPSC) technologies have transformed our ability to study disease in human neural cells. Here, we firstly review the progress made to model HD in vitro using patient-derived iPSCs, which reveal unique insights into illuminating molecular mechanisms and provide a novel human cell-based platform for drug discovery. We then highlight the promises and challenges for pluripotent stem cells that might be used as a therapeutic source for cell replacement therapy of the lost neurons in HD brains.

Keywords: Cell replacement therapy; Drug discovery; Huntington’s disease; Induced pluripotent stem cells; Stem cell models.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The generation and application of iPSCs in HD research. HD patient-specific iPSCs can be obtained by reprogramming of skin fibroblasts. Established iPSCs can be used as a tool for better understanding the molecular basis of HD. iPSC technology can also be coupled with high-throughput screening that provides a more efficacious platform to assess novel drug candidates aimed at stopping or slowing disease process. Moreover, HD-iPSCs can be differentiated into specific cell types predominantly affected in the disease (striatal MSNs). Emerging gene therapies make the genetic correction of HD-iPSCs become feasible, paving the way for autologous transplantation strategies of healthy iPSCs or iPSC-derived neural cells

Similar articles

Cited by

References

    1. Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218–228. doi: 10.1016/s0140-6736(07)60111-1. - DOI - PubMed
    1. Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ, Tulli S. The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci. 2014;21(3):112–114. doi: 10.5214/ans.0972.7531.210308. - DOI - PMC - PubMed
    1. Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98. doi: 10.1016/S1474-4422(10)70245-3. - DOI - PubMed
    1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–1091. doi: 10.1002/mds.25075. - DOI - PubMed
    1. Myers RH. Huntington’s disease genetics. NeuroRx. 2004;1(2):255–262. doi: 10.1602/neurorx.1.2.255. - DOI - PMC - PubMed

Publication types

LinkOut - more resources